XM không cung cấp dịch vụ cho cư dân của Mỹ.
B
B

BayerAG


Tin tức

India economic, corporate events on November 1

DIARY- India economic, corporate events on November 1 BENGALURU, Nov 1 (Reuters) - Diary of India economic, corporate events on November 1. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INLOAN=ECI 1 Nov 2024 17:00 Bank Loan Growth 18 Oct, w/e 12.8% INDEP=ECI 1 Nov 2024 17:00 Deposit Growth 18 Oct, w/e 11.8% INFXR=ECI 1 Nov 2024 17:00 FX Reserves, USD 25 Oct, w/e 688.27B Start Date Start Time RIC Company Name Event Name 01-Nov-2024 NT
B

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S

FMC beats third-quarter profit estimates on strong North America sales, lower costs

FMC beats third-quarter profit estimates on strong North America sales, lower costs Oct 29 (Reuters) - Agrichemicals firm FMC FMC.N beat Wall Street estimates for quarterly profit on Tuesday, helped by strong sales in North America and lower costs. FMC, which makes insecticide and fungicide, had seen a sharp drop in demand in 2023 as high inventory levels of crop chemicals across several regions had weighed in on earnings.
B
B
F

Ukrainian corn seed flows to Europe in further farm trade shift

ANALYSIS-Ukrainian corn seed flows to Europe in further farm trade shift Corn seed part of rise in Ukrainian farm exports to EU EU regulatory clearance and war fuelled seed trade EU growers fear competition, Ukraine sees own import reliance By Gus Trompiz and Pavel Polityuk PARIS/KYIV, Oct 24 (Reuters) - Ukraine has rapidly expanded exports of corn seed to the EU in the past two years in rare good news for its war-hit agricultural sector but adding to European farmers' grievances about what they
B
C

Bayer And Dewpoint Therapeutics Sign Licensing Agreement For Heart Disease Program

BRIEF-Bayer And Dewpoint Therapeutics Sign Licensing Agreement For Heart Disease Program Oct 24 (Reuters) - BAYER AG BAYGn.DE : BAYER AND DEWPOINT THERAPEUTICS SIGN LICENSING AGREEMENT FOR HEART DISEASE PROGRAM POST-LICENSING, COMPANIES WILL CONTINUE TO COLLABORATE ON CARDIOVASCULAR AND RENAL PROGRAMS DEWPOINT WILL RECEIVE AN UPFRONT AND ADDITIONAL
B

Bayer Announces Partnership With Impli

BRIEF-Bayer Announces Partnership With Impli Oct 24 (Reuters) - Bayer AG BAYGn.DE : BAYER AG - ANNOUNCED A PARTNERSHIP WITH IMPLI, AN INNOVATIVE, DEEP-TECH START-UP IN PRECISION CARE Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

Shell setback upsets Nigeria's quest to lure investment

ANALYSIS-Shell setback upsets Nigeria's quest to lure investment Exxon Mobil decision was approved but after long wait Shell has not commented and regulator has not explained Some investors see positive change By MacDonald Dzirutwe LAGOS, Oct 23 (Reuters) - Nigeria's decision this week to block Shell's SHEL.L $2.4 billion sale of its onshore assets has sent a negative signal to investors the country urgently needs to strengthen its all-important oil sector, analysts said.
B
G

Ashmore, Biomerieux, Diasorin

EUROPE RESEARCH ROUNDUP-Ashmore, Biomerieux, Diasorin Oct 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Ashmore, Biomerieux and Diasorin, on Thursday. HIGHLIGHTS * Ashmore ASHM.L : JP Morgan raises target price to 161p from 155p * Biomerieux BIOX.PA : HSBC raises target price to EUR 126 from EUR 120 * Diasorin DIAS.MI : HSBC cuts to hold from buy * Givaudan SA GIVN.S : Citigroup cuts target price to CHF 4650 from CHF 4750 * Oxf
A
A
A
A
B
B
C
D
E
E
G
G
I
L
L
S
T
W
Q
A
A
A
D
U

Australia's Enlitic gains on distribution deal with Bayer Healthcare

BUZZ-Australia's Enlitic gains on distribution deal with Bayer Healthcare ** Shares of Enlitic ENL.AX rise 14.1% to A$0.073, set for best day since Sept. 30, if current gains hold ** Healthcare technology firm says it has signed a three-year distribution contract with multinational biomedical co Bayer Healthcare ** Under the contract, Enlitic says
B

Bayer submits EU marketing application for menopause relief drug

Bayer submits EU marketing application for menopause relief drug Oct 15 (Reuters) - Bayer BAYGn.DE on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant. The daily pill was shown to ease hot flashes in a third late-stage trial that provided supporting data on efficacy and long-term safety.
B

Bayer applies for third indication of Nubeqa in EU

Bayer applies for third indication of Nubeqa in EU BERLIN, Oct 14 (Reuters) - Bayer BAYGn.DE said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy. It said the submission to the European Medicines Agency (EMA) was based on positive results from a phase III trial that showed darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or d
B

Bayer Submits Application For Third Indication Of Darolutamide In EU

BRIEF-Bayer Submits Application For Third Indication Of Darolutamide In EU Oct 14 (Reuters) - BAYER AG BAYGn.DE : SUBMITS APPLICATION FOR THIRD INDICATION OF DAROLUTAMIDE IN EU IS SEEKING APPROVAL FOR USE OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) SUBM
B

Bayer slips after verdict to pay $78 mln in Roundup cancer case

BUZZ-Bayer slips after verdict to pay $78 mln in Roundup cancer case ** Shares of Germany's Bayer BAYGn.DE slip 1.7% after a state court jury in Philadelphia found the company must pay $78 million in latest Roundup cancer trial ** The verdict follows previous consecutive victories for Bayer in that court ** New setback after PCB review, a local tra
B

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P

US judicial panel to examine litigation finance disclosure

US judicial panel to examine litigation finance disclosure By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers . After a decade of weighing whether it should do anything to regulate the emerging field of litigation finance, the U.S.
A
B
C
G
N
P

Bayer must pay $78 million in latest Roundup cancer trial, jury finds

UPDATE 2-Bayer must pay $78 million in latest Roundup cancer trial, jury finds Adds statement from plaintiffs' lawyers in paragraphs 3-4, background in paragraph 10 By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
B

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday. The verdict in state court in Philadelphia follows previous consecutive victories for Bayer in that court.
B

Bayer falls after US court accepts PCB case for review

BUZZ -Bayer falls after US court accepts PCB case for review ** Shares in Bayer BAYGn.DE fall 7%, with an analyst pointing to new developments in a case over unit Monsanto's toxic chemicals known as PCBs as the potential reason for the move ** Bloomberg on Wednesday reported that Washington state's Supreme Court accepted to review a case against Ba
B

Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA)

BRIEF-Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA) Oct 9 (Reuters) - BAYER AG BAYGn.DE : U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS NEW DRUG APPLICATION FOR ELINZANETANT Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.